CEO

I am a biomedical engineer and translational innovator specializing in the design, prototyping, and regulatory development of medical devices for complex and underserved health conditions. My work spans concept generation, engineering design, and clinical translation, with a focus on regenerative medicine, neurodevelopmental disorders, and neuromuscular diseases. As CEO of ARDIG Technologies Inc. and sponsor of multiple biomedical engineering senior design teams, I lead cross-disciplinary collaborations that transform early-stage ideas into functional, testable prototypes and guide them through design verification and pre-regulatory pathways. My early clinical experience as a medical scribe and shadow for Baptist Health South Florida and Vital Medical Center provided direct exposure to patient care and data collection, strengthening my ability to design devices informed by real-world clinical needs. Concurrently, my research in stem cell applications for Duchenne Muscular Dystrophy and in developmental disorders deepened my understanding of the physiological and ethical considerations that underpin device development for vulnerable populations. These experiences shaped my commitment to creating technologies that merge engineering precision with clinical purpose. Through ARDIG Corp., I have also directed international efforts integrating biomedical engineering with regenerative medicine practice. Working with clinical partners in Mexico and Peru, I’ve contributed to the design and refinement of medical systems that support stem cell therapies, fecal microbiota transplantation, and diabetes management in underserved areas. This work has emphasized process standardization, safety validation, and protocol reproducibility, all key translational pillars that parallel regulatory expectations for emerging biotechnologies. In the context of NIH-funded initiatives, I bring expertise in device concept translation, cross-functional team leadership, and regulatory strategy. I will contribute to engineering design reviews, prototype optimization, and early-stage validation to ensure that devices are manufacturable, testable, and compliant with FDA preclinical standards. My goal is to expand access to safe, innovative technologies that address critical gaps in regenerative and rehabilitative medicine, fostering a bridge between academic research, engineering innovation, and clinical impact.